Chase Investment Counsel Corp Has $536,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Chase Investment Counsel Corp decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 510 shares of the biopharmaceutical company’s stock after selling 97 shares during the period. Chase Investment Counsel Corp’s holdings in Regeneron Pharmaceuticals were worth $536,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. Sachetta LLC increased its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $28,000. Finally, Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Down 0.6 %

REGN opened at $821.00 on Wednesday. The stock has a fifty day moving average of $1,007.57 and a 200-day moving average of $1,037.30. The company has a market capitalization of $90.22 billion, a P/E ratio of 20.32, a P/E/G ratio of 3.12 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $784.96 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Analysts Set New Price Targets

A number of brokerages have recently commented on REGN. Royal Bank of Canada cut their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. TD Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,107.25.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.